Search for dissertations about: "Erik Sjögren"

Showing result 1 - 5 of 13 swedish dissertations containing the words Erik Sjögren.

  2. 1. Hepatic Disposition of Drugs and the Utility of Mechanistic Modelling and Simulation

    Author : Erik Sjögren; Hans Lennernäs; Scott Obach; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Hepatic disposition; pharmacokinetics; mechanistic modelling; drug-drug interactions; enzyme kinetics; Vmax; Km; CLint; carrier-mediated transport; active transport; modelling; in vitro-in vivo extrapolation; physiologically based pharmacokinetic model; optimal experimental design; experimental optimization; data analysis optimization; PHARMACY; FARMACI; Biopharmacy; Biofarmaci; Biopharmaceutics; Biofarmaci;

    Abstract : The elimination of drugs from the body is in many cases performed by the liver. Much could be gained if an accurate prediction of this process could be made early in the development of new drugs. However, for the elimination to occur, the drug molecule needs first to get inside the liver cell. READ MORE

  4. 2. In vitro evaluation of formulations used in the treatment of hepatocellular carcinoma

    Author : Emelie Ahnfelt; Hans Lennernäs; Erik Sjögren; Niklas Axén; Jesper Østergaard; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Drug delivery system; Doxorubicin; Microgel; Emulsion; Hepatocellular carcinoma; Biofarmaci; Biopharmaceutics;

    Abstract : Hepatocellular carcinoma (HCC) causes ~ 600,000 deaths annually, making it the second most deadly cancer form. HCC is classified into five stages and for the intermediate HCC treatment, the two most commonly used drug delivery systems (DDSs) are lipiodol-based emulsions and drug-eluting beads. READ MORE

  5. 3. Biopharmaceutical aspects of intestinal drug absorption : Regional permeability and absorption-modifying excipients

    Author : David Dahlgren; Hans Lennernäs; Erik Sjögren; Bertil Abrahamsson; Christer Tannergren; Steffansen Bente; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; intestinal permeability; absorption-modifying excipients; Biofarmaci; Biopharmaceutics;

    Abstract : Before an orally administered drug reaches the systemic circulation, it has to dissolve in the intestinal fluids, permeate across the intestinal epithelial cell barrier, and pass through the liver. The permeation rate of drug compounds can be low and show regional differences.The thesis had two general aims. READ MORE

  6. 4. Translational Tumor Drug Delivery : Doxorubicin formulation performance, intracellular uptake and molecular diffusion

    Author : Oliver Degerstedt; Hans Lennernäs; Erik Sjögren; Per Hansson; Jessica Rosenholm; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; doxorubicin; drug diffusion; cellular uptake; drug delivery; PBPK modelling; hepatocellular carcinoma; emulsion; IC50; Farmaceutisk vetenskap; Pharmaceutical Science;

    Abstract : Globally, hepatocellular carcinoma (HCC) is the most common form of liver cancer and a leading cause of cancer death. One important risk factor is liver cirrhosis and the disease progression is characterized by deposition of extracellular matrix proteins that form a fibrous network, which increases liver stiffness and may limit the effectiveness of different treatment strategies. READ MORE

  7. 5. Biopharmaceutical investigations of doxorubicin formulations used in liver cancer treatment : Studies in healthy pigs and liver cancer patients, combined with pharmacokinetic and biopharmaceutical modelling

    Author : Ilse R Dubbelboer; Hans Lennernäs; Erik Sjögren; Hartmut Derendorf; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; drug delivery system; in vivo release; PBPK modelling; hepatocellular carcinoma; doxorubicin; transarterial chemoembolization; drug disposition; Biofarmaci; Biopharmaceutics; Farmaceutisk vetenskap; Pharmaceutical Science;

    Abstract : There are currently two types of drug formulation in clinical use in the locoregional treatment of intermediate hepatocellular carcinoma (HCC). In the emulsion LIPDOX, the cytostatic agent doxorubicin (DOX) is dissolved in the aqueous phase, which is emulsified with the oily contrast agent Lipiodol® (LIP). READ MORE